Literature DB >> 8861805

Nephrotic syndrome associated with chronic lymphocytic leukemia resistant to immunosuppressive drugs: remission obtained by splenectomy.

J M Halimi1, T Lavabre-Bertrand, J J Beraud, B Canaud.   

Abstract

Chronic lymphocytic leukemia is a common disease in the elderly but is rarely associated with a nephrotic syndrome. The rarity of this association suggests that leukemic cells may have certain properties or features that may lead to the development of glomerulonephritis. Effective medical treatment of the leukemia may not necessarily allow regression of the nephrotic syndrome; however, the effects of splenectomy on nephrotic proteinuria when associated to chronic lymphocytic leukemia have never been evaluated. We report the case of a 50-year-old male with stage C CD5+ chronic lymphocytic leukemia associated with a nephrotic syndrome due to Type I membranoproliferative glomerulonephritis. Chlorambucil and prednisone were unable to control the leukemia and the nephrotic range proteinuria, and were discontinued because of poor hematologic tolerance. A splenectomy immediately resulted in a spectacular remission of both chronic lymphocytic leukemia and the nephrotic syndrome. Spleen lymphocytes were collected and tested in quantitative flow cytometry for the expression of the main B cell associated markers. They did not exhibit any particular immunophenotypic pattern. This report of a remission of a glomerulonephritis associated with chronic leukemia following splenectomy is evidence of a possible relationship between the two diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8861805

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  1 in total

1.  Membranoproliferative Glomerulonephritis Secondary to a Low-Grade Lymphoproliferative Disorder: A Rare Cause of Renal Dysfunction.

Authors:  Tushar Sehgal; Nidhi Jain; Gaurav Prakash; Ritambhra Duseja; Neelam Varma
Journal:  Indian J Hematol Blood Transfus       Date:  2016-06-14       Impact factor: 0.900

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.